JAK1 and hematopoietic and lymphoid cell neoplasm: For instance, bortezomib and ruxolitinib (a JAK1/2 inhibitor targeting STAT3) have shown promise in other hematologic cancers and may enhance therapeutic strategies when combined with BCR inhibitors.